The current classification of the World Health Organization (WHO, 2021) has significantly increased the role of molecular markers in defining tumor subtypes, leading to a redefinition of the term “glioblastoma”, which refers to high-grade tumors that meet IDH-wildtype criteria and specific molecular and histological characteristics [2]. The gene discussed is IDH2; the disease is neoplasm.